Zantac Recall Cancer Lawsuit Update, April 3, 2020:
By Julie Oliver-Zhang, Esq. and Rachel Wei, Esq.
The U.S. Food and Drug Administration (FDA) announced on April 1, 2020 that it is requesting manufacturers to immediately withdraw all prescription and over-the-counter (OTC) ranitidine drugs, commonly known as Zantac, from the market. A contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications is a probable human carcinogen. The FDA found that NDMA in some ranitidine products increases over time and when stored at higher than room temperatures. This results in consumer exposure to unacceptable levels of this carcinogenic impurity. Disturbingly, new FDA testing confirmed that the carcinogenic NDMA levels increase in ranitidine even under normal storage conditions
On February 10, 2020, 15 Zantac lawsuit plaintiffs have been transferred to South District of Florida court, where a multidistrict litigation (MDL) has been filed on behalf of individuals who have been diagnosed with cancer subsequent to taking Zantac and similar ranitidine products. According to the transfer order, which was approved by federal judges, there are currently 126 cases pending in 21 districts nationwide. The Zantac lawsuit MDL currently consists both of individual plaintiffs alleging personal injury and punitive damage class action lawsuits.
Oliver-Zhang Law is representing clients nationwide who were diagnosed with cancer after exposure to Zantac. Please contact our Zantac attorneys at [email protected], or 202-643-1110 to see if you are eligible to claim compensation for your cancer injuries in the ongoing Zantac cancer litigation.